Wellyfe

Hospitals Are Ready to Play Offense—Are You? For too long, health systems have been stuck in defense mode, battling rising costs, declining reimbursements, and PBMs siphoning revenue out of their pharmacy programs. But now, according to Becker’s Hospital Review, C-suite leaders are shifting gears—it’s time to go on offense. ?? The Biggest Opportunity in Healthcare Finance? Your Pharmacy Program. Hospitals that take control of their pharmacy benefits and specialty drug spend are unlocking millions in savings and new revenue streams. Yet, too many are still letting middlemen dictate pricing, keep rebates, and control patient access. At Wellyfe, we help health systems own the pharmacy benefit and reclaim lost dollars by: ? Eliminating PBM Spread Pricing – Stop overpaying and take control of every drug dollar. ? Capturing More 340B Savings – Align your contract pharmacy strategy for maximum savings retention. ? Expanding Specialty Pharmacy Revenue – Specialty drugs account for 50%+ of spend—it’s time for hospitals to own that margin. ? Direct-to-Employer Pharmacy Contracts – Compete directly with PBMs to offer employers better, more affordable pharmacy benefits. Hospitals cannot afford to leave pharmacy dollars on the table. The path forward is clear—own the pharmacy, own the savings. ?? Wellyfe partners with health systems to build and execute direct pharmacy care strategies that drive real financial impact. Let’s talk about what’s possible for your organization. ?? DM us or visit www.wellyferx.com to learn more. #HospitalFinance #PBMReform #DirectPharmacyCare #340B #SpecialtyPharmacy #Wellyfe #PharmacyRevenue #HealthcareInnovation https://lnkd.in/gMf2pVzf

Specialty drugs are one of the biggest rackets in the American healthcare system. Because once a drug is labeled “specialty,” pharmacies and patients can only purchase it from the PBM. Who decides which drug is specialty? The PBM. (And they each have a different list... revealing how arbitrary this is.) And who sets the price of the drug? Also the PBM. This is how prices become bloated to 30x the cost of a generic version. And it needs to stop.

Just the tip of the iceberg! ?? There is an unbelievable amount of money being sucked from our community employers and independent pharmacies. ?? If you are curious about your data and the story it tells, Logan Lyle is a wizard! Let's explore how you can optimize your pharmacy benefits!

?? Is the Traditional PBM Model Broken Beyond Repair? ?? The pharmacy benefit landscape is shifting, and the question on every employer’s mind is: Are we paying for savings we never see? Traditional PBMs have long promised cost control, but the reality is hidden fees, spread pricing, and rebate games—all at the expense of patients and employers. ?? What’s Trending in Pharmacy Benefits: ? The Rise of Transparent Models: Employers are demanding 100% pass-through rebates and lowest-net-cost strategies. ? Biosimilars Are Taking Center Stage: Employers who switch to biosimilars are seeing 40-60% cost reductions on high-cost drugs like Humira. ? In-House PBMs and Direct Pharmacy Care: Health systems are cutting out the middleman and driving millions in savings through direct pharmacy models. ?? At Wellyfe, we believe the solution is simple: ? Eliminate Spread Pricing: Transparent pricing models, no hidden markups. ? Maximize Rebates: 100% rebate pass-through, every dollar back to the employer. ? Leverage Biosimilars & Generics: Clinical efficacy at a fraction of the cost. The time for status quo is over. It’s time for employers to own their pharmacy destiny and drive meaningful savings while improving patient care. ??

?? Maximizing 340B Capture Rates: Steps for Success The 340B Drug Pricing Program is a powerful tool for health systems, FQHCs, and covered entities to expand access and reinvest in patient care. Yet, many organizations are leaving significant savings on the table due to inefficiencies in program management. Here’s how to maximize your 340B capture rates and ensure your organization is fully leveraging its benefits: ? Data Optimization – Ensure accurate claims matching across eligible encounters and prescriptions. ? Contract Pharmacy Efficiency – Strengthen relationships and oversight with contract pharmacies to increase eligible prescriptions. ? Prescriber Alignment – Educate providers on proper documentation and enhance workflows to ensure all qualifying prescriptions are captured. ? Regular Compliance Audits – Proactively monitor drug diversion risks and duplicate discounts to stay compliant while maximizing savings. ? Technology & Analytics – Leverage advanced reporting tools to track, analyze, and improve 340B participation rates. The Bottom Line: A well-optimized 340B program doesn’t just cut costs—it expands care. Health systems that strategically manage their 340B capture rates can unlock new revenue streams while increasing medication access for vulnerable populations. Is your 340B program operating at its full potential? Let’s discuss how Wellyfe can help. ??

?? Expanding Access, Strengthening Communities: The Power of 340B Programs ?? Healthcare access is more than just a service—it’s a lifeline. The 340B Drug Pricing Program plays a critical role in ensuring that hospitals and community health centers can stretch limited resources to serve vulnerable populations. But how exactly does it impact patient care? ?? Affordable Medications – Patients facing financial hardship gain access to lower-cost prescriptions, reducing barriers to essential treatments. ?? Funding for Essential Services – 340B savings help fund expanded clinical programs, mental health services, and outreach initiatives. ?? Better Health Outcomes – By enabling medication adherence, the program supports chronic disease management and preventive care, reducing hospital readmissions. ?? Support for Rural and Underserved Areas – Many critical access hospitals and FQHCs rely on 340B to sustain operations and ensure care for uninsured and underinsured patients. Despite its proven benefits, 340B faces ongoing challenges from policy changes and industry pressures. Now, more than ever, healthcare leaders must advocate for its preservation. ?? How has the 340B program impacted your community or healthcare organization? Let’s discuss how we can protect and enhance its reach.

When the ‘benefit’ in pharmacy benefits means paying more than cash, something’s broken. The Big 3 PBMs profit from complexity and hidden fees, but transparency-driven models, like Direct Pharmacy Care, cut through the nonsense. Wellyfe helps organizations take back control, ensuring pharmacy spend actually benefits members, plans, and the community as a whole. It’s time for change! Let’s talk ??

?? The Financial Impact of Optimized 340B Programs: A Closer Look Healthcare organizations often underestimate the true potential of their 340B programs. It’s not just about compliance—it’s about unlocking hidden financial opportunities that can directly impact patient care and organizational sustainability. At Wellyfe, we’ve seen how an optimized 340B program can: ?? Recover millions in unrealized savings ?? Improve data transparency and operational efficiency ?? Reinvest in patient programs that drive better health outcomes But here’s the challenge: Many health systems leave money on the table due to outdated strategies and fragmented oversight. ? Are your contract pharmacy relationships truly maximizing revenue? ? Is your program data being leveraged for real-time decision-making? ? Are you compliant and capitalizing on every opportunity to expand access? The financial impact is clear—optimized 340B programs aren’t just cost-saving tools; they’re revenue-generating assets. ?? What’s holding your 340B program back from its full potential? Let’s start the conversation.

?? PBM Cost Transparency: A Breakdown of Savings Opportunities ?? For too long, PBM pricing has been a black box, filled with hidden fees, spread pricing, and rebates that rarely make their way back to employers, health systems, or patients. At Wellyfe, we believe in shining a light on where your dollars are really going—and more importantly, how you can take control of your pharmacy spend. ?? Where Are the Hidden Costs? ? Spread Pricing – PBMs charge payers more than they reimburse pharmacies, keeping the difference. ? Rebate Retention – A large portion of manufacturer rebates never reach employers or patients. ? Opaque Pricing Models – Complex contract structures make it difficult to track true costs. ? Clawbacks & Admin Fees – Hidden fees that chip away at potential savings. ?? Where Are the Savings Opportunities? ?? Pass-Through Pricing – Know exactly what you're paying, with 100% of rebates returned. ?? Direct Contracting – Cut out unnecessary middlemen and negotiate real cost savings. ?? Transparent Data Access – Understand where every dollar goes to make informed decisions. ?? Optimized 340B & In-House Pharmacy Models – Keep more of your savings in-house where it belongs. It’s time to challenge the status quo. If your PBM isn’t fully transparent, then it’s time to ask—who’s really benefiting from your pharmacy spend? ?? Let’s start the conversation on how Wellyfe is helping organizations take back control and unlock real cost savings.

?? Are PBM Costs a Major Issue for Your Organization? Pharmacy Benefit Managers (PBMs) play a critical role in managing prescription drug benefits, but for many organizations, their costs can feel like a black box. Hidden fees, spread pricing, and opaque rebate arrangements often leave employers, hospitals, and health systems wondering: ?? Are we really getting the value we’re paying for? At a time when every dollar matters, understanding where your PBM dollars go—and how they could be better spent—is more important than ever. ?? We want to hear from you! Take a moment to respond to the poll below: ?? Are PBM Costs a Major Issue for Your Organization? Your insights matter. Let’s start the conversation about what’s working, what isn’t, and how we can create solutions that truly align with organizational goals and patient care. ?? Ready to explore innovative, transparent alternatives? Let’s connect and discuss how you can take control of your pharmacy benefit strategy.